Statin policy and target populations: Evidence-based or evidence-biased?

Current Opinion in Lipidology

Volumn 15, Issue 4, 2004, Pages 381-386

  Durrington, Paul ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL OBSERVATION; CLINICAL TRIAL; DISEASE COURSE; DRUG POTENCY; DRUG TARGETING; EDITORIAL; EVIDENCE BASED MEDICINE; FATALITY; HEALTH CARE; HEALTH CARE POLICY; HEMOCONCENTRATION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; LABORATORY; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PATIENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STANDARD; SYNDROME; TREATMENT INDICATION;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HEALTH POLICY; HEALTH SERVICES NEEDS AND DEMAND; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POLICY MAKING; RISK; SYNDROME;

EID: 4043055184     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000137223.61901.a9     Document Type: Editorial

References (37)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22. The largest most comprehensive randomized, placebo-controlled statin trial yet.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326:1423-1427.
4. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757-767.
5. Reckless JPD. Cost-effectiveness of statins. Curr Opin Lipidol 2000; 11:351-356,
6. Jackson PR, Ramsay LE. Debate: at what level of coronary heart disease risk should a statin be prescribed? Curr Opin Lipidol 2000; 11:357-361.
7. Gaw A, Packard CJ. At what level of coronary heart disease risk should a statin be prescribed? Curr Opin Lipidol 2000; 11:363-367.
8. Durrington PN. Dyslipidaemia. Lancet 2003; 362:717-731. A summary of our current knowledge of the pathophysiology and clinical features of the various dyslipidaemic syndromes.
9. Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation 2000; 102:157-165.
10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504. A trial showing the superiority of achieving LDL cholesterol levels with statin treatment lower than currently recommended for secondary prevention.
11. Hegele RA. Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. Am J Hum Genet 2001; 69:1161-1177.
12. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 2003; 170:145-155.
13. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 2001; 285:2486-2497.
14. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
15. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between, patients with type 2 diabetes and those who had had a myocardial infarction: cross section and cohort studies. BMJ 2002; 324:939-941.
16. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990; 121:293-298.
17. Stevens RJ, Kothari V, Adler AI, et al., for the UK Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci 2001; 101:671-679.
18. National Institute of Clinical Excellence. Management of type 2 diabetes. Management of blood pressure and blood lipids. Inherited Clinical Guideline H. Ref. no. 167. London: NICE; 2002.
19. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary disease start ticking before the onset of clinical diabetes. JAMA 1990; 263:2893-2898.
20. Wood D, Durrington PN, Poulter N, et al. Joint British Recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl 2):S1-S29.
21. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British guidelines on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320:705-708.
22. Available on: www.medicine.man.ac.uk/stopmed. [Accessed 27 May 2004]. Website for Cardiovascular Research Group based at the University of Manchester click onto the 'Download Coronary Risk Prediction Method' this will give you access to the coronary risk prediction methods file.
23. Shaper AG, Pocock SJ, Phillips AN, Walker M. Identifying men at high risk of heart attacks: strategy for use in general practice. BMJ 1986; 293:474-479.
24. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol - Scandinavian Cardiac Outcomes Trial - Lipid lowering arm (ASCOT-LLA): on multicentre randomised controlled trial. Lancet 2003; 361:1149-1158. A randomized placebo-controlled trial of a statin in patients in the lower part of the cholesterol distribution in a large trial comparing antihypertensive agents which was stopped prematurely because of a favourable effect in those actively treated.
25. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomised trials. JAMA 1997; 278:313-321.
26. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
27. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356:1955-1964.
28. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line anti-hypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356:1949-1954.
29. Dyslipidaemia Advisory Group, on behalf of the Scientific Committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation Guidelines for the Assessment and Management of Dyslipidaemia. NZ Med J 1996; 109:224-232.
30. Durrington PN, Prais H, Bhatnagar D, et al. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet 1999; 353:278-281.
31. Morris RW, Whincup PH, Lampe FC, et al. Geographic variation in incidence of coronary heart disease in Britain: the contribution of established risk factors. Heart 2001; 86:277-283.
32. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society Guidelines. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18:139-185. The latest British Hypertension Society guidelines which also reveal the current thinking of the Joint British Societies Committee on cholesterol-lowering.
33. National Health Service Framework for Coronary Heart Disease. London: Department of Health; March 2000. Available at: www.doh.gov.uk/nsf/coronary. htm#chdnsf. [Accessed 27 May 2004].
34. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 2003; 361:777-780. A summary of the evidence for the use of apolipoproteins as indicators of coronary risk and as therapeutic targets.
35. Genest J, Frohlich J, Fodor G, McPherson R, and the Working Group on Hypercholesterolemia and other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update. Full text available online: www.cmaj.ca/cgi/content/full/169/9/921/DC1. [Accessed 27 May 2004].
36. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR-spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003; 167:243-255.
37. Durrington PN. Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? Clin Chem 2002; 48:401-402.